F&P Healthcare raises full-year guidance
Another positive update from NZ respiratory products group, Fisher & Paykel Healthcare (ASX:FPH), on Friday.
Read MoreTag: FPH
Fisher & Paykel Healthcare reports improved financials
A slightly higher dividend was announced for its 2023-24 financial year, along with expectations for a slightly better result in 2024-25, by New Zealand-based Fisher & Paykel Healthcare Corporation (ASX:FPH) on Wednesday.
Read More
Fisher & Paykel Healthcare raises dividend
New Zealand-based Fisher & Paykel Healthcare Corporation has increased its interim dividend from 17.5 NZ cents to 18 NZ cents for the six months ending September 30, following a robust performance with a 16% rise in revenue and a 12% increase in after-tax earnings.
Read MoreFisher & Paykel continues to excel with post-pandemic strategies
Fisher & Paykel Healthcare Corporation looks on track to make guidance for the six months to September and the full financial year ending March 2024.
Read MoreBreakfast Bites: FPH, AUC
Let’s start the new week with a couple quick stories we couldn’t fit into our bumper weekend edition, involving Fisher & Paykel Healthcare and Ausgold.
Read MoreImpeccable Bill of Health for Fisher & Paykel
Shares in Fisher and Paykel Healthcare leapt 14% yesterday after the company produced a forecast for a second half improvement on what was a solid first six-months.
Read MoreSleepless Nights for Rivals after Philips Warning
Concerns for Resmed and Fisher and Paykel Healthcare after a surprise profit warning from Philips, their big Dutch rival in the sleep and respiratory sectors, saw its share price hit 10-year lows.
Read MoreFPH – Citi rates the stock as Buy
Buy rating retained. Target price falls to NZ$24 from NZ$25.75.
Read MoreIndustrials Intel: CGC, FPH, ALQ
Things were also busy across in the ASX Industrials sector. Here’s some news released during the Wednesday session by Costa Group, Fisher & Paykel Healthcare and ALS Ltd.
Read MoreFPH – Macquarie rates the stock as Outperform
The Outperform rating is retained and the target price decreases to NZ$29.87 from NZ$37.57.
Read MoreFPH – Credit Suisse rates the stock as Neutral
The Neutral rating is retained and the target price decreases to $27.00 from $34.00.
Read MoreFisher & Paykel Left Short of Breath
New Zealand-based medical products group Fisher and Paykel has confirmed full year revenue will be down sharply from 2020-21’s Covid boosted record of more than $NZ1.9 billion.
Read MoreRelief Rally Sees Fisher & Paykel Jump 5%
Shares in Fisher and Paykel Healthcare jumped more than 5% at one stage yesterday despite a flat performance for the six months to September 30 and weak outlook for some parts of the business.
Read MoreFPH – Macquarie rates the stock as Neutral
The stock is still considered expensive and a Neutral rating is maintained. Target is raised to NZ$32.30 from NZ$31.84.
Read MoreFPH – UBS rates the stock as Sell
UBS retains a Sell rating, believing the stock is overvalued and there will be negative earnings momentum as covid-19 hospitalisation rates fade. Target is NZ$22.65.
Read MoreFPH – UBS rates the stock as Sell
The Sell rating and target price of $22.65 are retained.
Read MoreFPH Announces 61% Profit Jump, Shares Fall 6%
Shares in New Zealand medical technology group Fisher & Paykel Healthcare took a pounding yesterday despite the company turning in a stellar result for its 2021 financial year.
Read MoreFPH – Credit Suisse rates the stock as Outperform
The target price is increased to $34 from $33.50 and the Outperform rating is maintained.
Read MoreFPH – UBS rates the stock as Sell
Fisher & Paykel Healthcare Corp’s latest trading update showed larger-than-expected covid-led hospital sales. UBS sees a material drop in earnings over the next 18 months and maintains its Sell rating. Target rises to NZ$23.40 from NZ$21.35.
Read MoreCOVID Still Driving FPH Revenue as Earnings Surge
Fisher & Paykel Healthcare has seen worldwide demand for its breathing devices continue to soar during pandemic, boosting revenue 73% in the nine months to the end of December.
Read MoreCOVID Demand Drives Record Profit At Fisher & Paykel Healthcare
A small dip yesterday in the Fisher and Paykel Healthcare (FPH) share price, despite a solid interim result confirmed the company has had a nice ride on the back of the COVID-19 pandemic.
Read MoreAustralian Healthcare: 10 Years In 10 Charts
With Alphinity celebrating its 10th anniversary we have explored what has happened in the healthcare sector in the decade since Alphinity was first established.
Read MoreFPH – UBS rates the stock as Sell
UBS finds home high flow therapy (HFT) to be an exciting opportunity and a natural extension of Fisher and Paykel Healthcare Corp’s technology from hospital into the home. However, the broker also admits progress has been “painfully slow” when it comes to building clinical evidence and gaining insurance coverage.
Read MoreStrong Demand Pushes Fisher & Paykel Healthcare Shares Higher
ASX-listed shares in Fisher & Paykel Healthcare (FPH) surged more than 6% in yesterday’s big sell-off after New Zealand’s most valuable company posted a 37% jump in its annual profit to a record $NZ287 million as the coronavirus caused an unprecedented increase in demand for its products.
Read MoreFPH – UBS rates the stock as Sell
UBS notes initial attempts to assess sales related to the pandemic were based on high estimates of infection rates, available ICU beds and manufacturing capability.
Read MoreFPH – Macquarie rates the stock as Neutral
Macquarie suspects the spread of coronavirus could have a modest impact on profit expectations. The broker assesses US/European hospitals are unlikely to require additional hardware to cope with the epidemic, as was the case in China.
Read MoreRecord Result Puts Fisher & Paykel In Good Health
Fisher & Paykel Healthcare says 2018-19 was a record year for revenue and profits and expects to do even better in the 2019-20 financial year with a forecast of a 15% or so lift in net earnings.
Read MoreFPH – UBS rates the stock as Sell
After reviewing the Vapotherm results, UBS believes the competitive threat to Fisher & Paykel is modest.
Read MoreFisher & Paykel Healthcare Lifts H1 Profit 20%
A rare riser in yesterday’s tide of red ink was NZ-based Fisher & Paykel Healthcare in the wake of what looks like a solid 2018-19 interim result forecast for the coming year.
Read More
